Hepatitis B Antigen Kidney Graft Into Protective Level Hepatitis B Antibody Recipients

January 22, 2014 updated by: Wiwat Chancharoenthana, Chulalongkorn University

The Outcomes of Kidney Transplantation Between Recipients Receiving Graft From Donors With Positive and Negative HBsAg

To determine the safety of using kidney organ from hepatitis B surface antigen positive donor, the author conducted the single-center, prospective study of the use of these kidneys for recipients who have protective level of hepatitis B surface antibodies.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

The kidney transplant registry was conducted in KCMH since the year of 2000 until the present.

The inclusion criterion was:

  • All kidney allograft recipients who received at least one month after transplantation.
  • All kidney recipients who already had the protective antibody against hepatitis B virus infection defined by anti-HBs titer above 100 mIU/mL at pre-transplantation period.

The exclusion criterion was:

  • The recipients with positive hepatitis C virus antibody.
  • The recipients who had received a previous or simultaneous non-kidney solid organ transplant.
  • The recipients those lost to follow-up.

Study group:

  • The recipients who received kidney allograft from the HBsAg(+) donor.

Control group:

  • The recipients who received kidney allograft from the HBsAg(-) donor.

According to the Thai Red Cross National Organ Donation and our institute's policy, the HBsAg(+) kidney allografts were distributed to only and informed consent.

Data collection:

  • Baseline characteristic data e.g. donor and recipient age, donor and recipient gender, HLA, PRA, anti-HBs titer, immunity against HBV status (both natural and vaccinated),immunosuppressive regimens were collected.
  • The recipients were prospective followed up at month 3, 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120.
  • Clinical data including jaundice, hepatitis, graft rejection were collected
  • Laboratory data of HBsAg, anti-HBc, HBV DNA, SGOT, SGOT, eGFR were collected.
  • Pathological data of allograft biopsy at month 12 and 24 were retrieved.

Outcomes:

  • Primary outcome: hepatitis B transmission rate.
  • Secondary outcome: graft survival, patient survival.

Study Type

Observational

Enrollment (Anticipated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Thailand
      • Bangkok, Thailand, 10330
        • Recruiting
        • Wiwat Chancharoenthana
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All kidney transplant recipients from January 1, 2000 until the present (upto year 2013) were prospective follow-up.

Description

The inclusion criterion was:

  • All kidney allograft recipients who received at least one month after transplantation.
  • All kidney recipients who already had the protective antibody against hepatitis B virus infection defined by anti-HBs titer above 100 mIU/mL at pre-transplantation period.

The exclusion criterion was:

  • The recipients with positive hepatitis C virus antibody.
  • The recipients who had received a previous or simultaneous non-kidney solid organ transplant.
  • The recipients those lost to follow-up.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
HBsAg negative kidney allograft donor
HBsAg positive kidney allograft donor
Biological: HBsAg positive kidney allograft donor

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hepatitis B transmission rate
Time Frame: January 2000 to December 2013

The hepatitis B transmission rate was determined at month 3, 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120 by using:

  • Clinical data including jaundice, hepatitis, acute liver failure.
  • Laboratory data of HBsAg, anti-HBc, HBV DNA, SGOT, SGOT.
  • Radiological data of liver ultrasonography.
January 2000 to December 2013

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Graft survival rate
Time Frame: January 2000 to December 2013
The graft survival rate was determined by Kaplan-Meyer survival analysis.
January 2000 to December 2013

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient survival rate
Time Frame: January 2000 to December 2013
The patient survival rate was determined by Kaplan-Meyer survival analysis.
January 2000 to December 2013

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Chulalongkorn University

Investigators

  • Principal Investigator: Wiwat Chancharoenthana, MD, MSc, Chulalongkorn University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2000

Primary Completion (Anticipated)

December 1, 2014

Study Registration Dates

First Submitted

January 20, 2014

First Submitted That Met QC Criteria

January 22, 2014

First Posted (Estimate)

January 24, 2014

Study Record Updates

Last Update Posted (Estimate)

January 24, 2014

Last Update Submitted That Met QC Criteria

January 22, 2014

Last Verified

January 1, 2014

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • WWC-001

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on HBsAg(+) Donor Kidney Allograft

Clinical Trials on HBsAg positive kidney allograft donor

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe